Phase III trials (FIDELIO-DKD, FIGARO-DKD) demonstrated finerenone reduced urinary albumin-to-creatinine ratio and delayed renal composite endpoints in T2D patients with CKD stages 3–4 (116). This evidence concerns the gene ALB and chronic kidney disease.